Out of the Lab: Operationalizing Cell and Gene Therapy

In this episode of Out of the Lab, host Nico sits down with 20-year cell and gene therapy expert Alfred Sloan to dissect the operational and capital constraints facing advanced therapy development today.

From the pressure to rapidly accelerate clinical timelines to the rising threat of global competition outcasting domestic manufacturing costs, Alfred breaks down why the industry must shift from isolated IP retention to scalable, repeatable manufacturing frameworks.

Key Discussion Points:
The Scalability Gap: Why existing technologies fail to scale seamlessly from research to commercial production.

Global Competition & Medical Tourism: How overseas government subsidies and collaborative models threaten to outpace US manufacturing within five years.

Tech Transfer Traps: Why handing over a paper SOP to a CDMO leads to $100,000 run failures and how continuous technical support bridges the gap.

Operational Cost Reduction: Navigating master service agreements, expediting fees, modular "widget" approaches, and standardizing assembly-line manufacturing.

Timestamps:
00:01:25 – Capital Constraints and Clinical Acceleration

00:03:27 – The Scalability Bottleneck Across Development Stages

00:06:28 – Breaking Down Knowledge Sharing and IP Barriers

00:11:36 – Global Competition, Government Subsidies, and Medical Tourism

00:16:43 – Operational Cost Reduction: Vendor Lock-In, Expediting Fees, and Modular Systems

00:20:50 – Tech Transfer Realities: The Limits of Paper SOPs and Scaling Microliters to Liters

00:26:26 – Asset Acquisition vs. Building from Scratch

00:33:27 – Supply Chain Vulnerabilities, Reagent Shortages, and Modular Platforms

How do 1 in 16 cell and gene therapies fail, not because of the biology, but because of the supply chain?

In this episode of Out of the Lab, host Nico sits down with Mehran, a seasoned Cell & Gene Therapy supply chain consultant, to dissect why operational resilience must be engineered into your product long before tech transfer ever takes place.

From CDMO selection gaps to un-addressable spend and non-standard Bill of Materials (BOM) choices, Mehran exposes the hidden operational traps that trigger FDA Complete Response Letters (CRLs) and derail launches.

In this episode, we cover:
Who Owns Resilience? Why supply chain expertise must intersect with early CMC and process development.

The CDMO Bottleneck: Unpacking why 40% of manufacturing-related FDA hurdles stem from partner selection and process optimization gaps.

Addressable vs. Non-Addressable Spend: Why 42% of materials get locked in filings and how to optimize raw material selection up front.

Real-World Harmonization: Lessons from J&J’s Carvykti pipeline on managing apheresis variability and standardizing network supply.

The Future of Orchestration: How AI and predictive analytics are transforming patient slotting, scheduling, and apheresis quality.

Timestamps & Chapters:
00:00 – Introduction: Supply chain resilience in Cell & Gene Therapy

02:03 – Who owns resilience? Bridging CMC, process development, and supply chain

04:57 – CDMO partner selection & commercial readiness

06:21 – The cost of failure: CRLs, manufacturing quality, and CDMO gaps

08:05 – Process ownership vs. CDMO lock-in: Lessons from J&J and apheresis

12:21 – Addressable vs. non-addressable spend in biomanufacturing

16:38 – The 50 mL Syringe Example: Why process engineers need supply chain optics

20:15 – Geopolitical risk, tariffs, and global facility harmonization

24:18 – Built-in network resilience: Lessons from radiopharmaceuticals

28:20 – Logistics, cold-chain, and patient orchestration in Europe vs. US

34:34 – The role of data, AI, and predictive analytics in apheresis quality

What happens when a foreign manufacturer gets put on an FDA import alert? Or when a single undocumented ingredient turns a harmless dietary supplement into an unapproved drug?

In this episode of Out of the Lab, host Nico sits down with Dan and Binh from Wynngate Consulting. Bringing decades of insider FDA experience from compliance enforcement to foreign facility inspections, they pull back the curtain on the operational realities of GXP manufacturing. We explore the massive regulatory shifts brought on by the Food Safety Modernization Act (FSMA) and why the FDA's Foreign Supplier Verification Program has changed the game for importers.

In this episode, we cover:
The Overlapping 50%: The surprising similarities and critical differences between dietary supplement GMPs (Part 111) and pharmaceutical GMPs (Part 211).

The "Checking the Box" Trap: How an inadequate response to an FDA 483 observation can escalate into an Import Alert and a 10-year remediation nightmare.

Intentional vs. Accidental Adulteration: From shared line cross-contamination to companies secretly lacing weight-loss supplements with active pharmaceuticals to dodge clinical trials.

The Old FDA Adage: Why you can never test quality into a product once underlying GMP violations exist.

Supply Chain Resilience: Why vetting your foreign CDMO's quality management system is the ultimate risk mitigation technique for drug sponsors.

Dan and Binh consult on GxP compliance at Wynngate Consulting.Connect with them:

Dan Simonsen, Vice President: https://www.linkedin.com/in/danjsimonsen/

Binh Nguyen, President: https://www.linkedin.com/in/binh-nguyen-a77046190/

Visit their website:https://www.wynngateconsulting.com/

What are the hidden operational mistakes early-stage drug developers make before ever selecting a CDMO?
In this episode of Out of the Lab, host Nicholas Crudele sits down with David Dismuke, Chief Technology Officer at Forge Biologics. Drawing on over 20 years of experience across both academic CDMOs, corporate CDMOs, and therapeutic developers, David breaks down why yield should not be your only metric, how host cell DNA and empty/full ratios impact clinical timelines, and why a low-CV potency assay is your ultimate insurance policy during tech transfer.
In this episode, we cover:
The Yield Trap: Why focusing solely on viral titer masks critical quality attributes (CQAs) that can derail regulatory filings.

Empty vs. Full Capsid Ratios: Managing host cell DNA trade-offs and understanding route of administration impacts.

Potency Assays as Comparability Anchors: How high-throughput, sound analytical methods allow you to innovate safely in GMP environments.

Two-Sided Tech Transfer: Why you should never "throw the process over the wall" and how to execute proper gap analyses with your CDMO.

Single-Use Equipment: Navigating downstream chromatography hurdles and eliminating multi-product contact risks.

Why do biomanufacturing execution systems fail despite multi-million dollar investments?
In this episode of Out of the Lab, host Nicholas Crudele sits down with biopharma automation and manufacturing execution system (MES) consultant Robert Perks to unpack the realities of digitizing biomanufacturing workflows. From early R&D data integration to navigating the FDA’s shift toward Computer Software Assurance (CSA), Robert shares what it actually takes to achieve release by exception.

Key Topics Covered:
Cross-Functional Ownership: Why MES implementations fail when controlled by a single department.

CSV to CSA Shift: Moving away from binders of paper to risk-based critical thinking.

Designing for the Operator: Eliminating duplicated data entry and friction on the cleanroom floor.

Bridging R&D and Manufacturing: Leveraging early KPI and CQA data to build standardized Master Batch Records (MBRs).

Release by Exception: What infrastructure is required to make automated batch release a reality.

Timestamps:
00:00:00 – Introduction & Operational Scope

00:01:14 – What is an MES & Who Needs a Seat at the Table?

00:03:12 – When Should Early Biotechs Engage with MES?

00:07:55 – Operator Optimization & Reducing Data Duplication

00:11:46 – The Regulatory Paradigm Shift: From CSV to CSA

00:18:48 – Integrating R&D Data into Scale-Up Master Batch Records

00:26:44 – The Holy Grail: Achieving Release by Exception